Oral Glutamine in Cardiopulmonary Bypass
Ischemic Heart Disease
About this trial
This is an interventional treatment trial for Ischemic Heart Disease focused on measuring Cardiac Surgical Procedures, Cardiovascular Surgical Procedures, Dietary Supplements, Glutamine, TROPONIN I, cardiopulmonary bypass
Eligibility Criteria
Inclusion Criteria:
- Patients with a confirmed diagnosis of Ischemic heart disease in whom cardiac revascularization (cardiac by pass) was going to be performed.
- Written informed consent from each patient.
Exclusion Criteria:
- Preexisting kidney disease
Liver dysfunction
.Drug or alcohol abuse Positivity to human immunodeficiency virus (HIV)
- Hepatitis B / C
- Allergies against components of GLN.
- Patients with an ongoing ischemia, defined by persistent elevation of TROP-I and CPK-MB levels.
- If any dietetic supplement of GLN was taken simultaneously.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
GLN group
CONT group
All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.